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Hyperactivation of systemic renin–angiotensin system (RAS)
during sepsis is well documented. However, the behavior of
intrarenal RAS in the context of endotoxemia is yet to be
defined. The present study evaluates the direct effect of
Escherichia coli lipopolysaccharide (LPS) on immortalized
human mesangial cell (HMC) RAS. Quiescent HMC were
incubated with vehicle or LPS (1–100 lg/ml), and levels of
angiotensin I and II (Ang I and II) and their metabolites were
analyzed by high-performance liquid chromatography. In
addition, angiotensin-converting enzyme (ACE) and renin
activity were also investigated. Cell lysate and extracellular
medium levels of Ang II were rapidly reduced (1 h) in a
time- and concentration-dependent manner, reaching a
significant 9 fold-change (Po0.001) after 3 h of LPS
incubation. Similar results were obtained for Ang I levels
(3 fold-change, Po0.001). We ruled out Ang I and II
degradation, as levels of their metabolic fragments were also
significantly decreased by LPS. ACE activity was slightly
increased following LPS incubation. On the other hand, renin
activity was significantly inhibited, as Ang I concentration
elevation following exogenous angiotensinogen
administration was blunted by LPS (60% vs vehicle,
Po0.001). Renin and angiotensinogen protein levels were
not affected by LPS according to Western blot analysis. Taken
together, these data demonstrate for the first time that LPS
significantly downregulates HMC RAS through inhibition of
renin or renin-like activity. These findings are potentially
related to the development of and/or recovery from acute
renal failure in the context of sepsis.
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Sepsis and septic shock, in particular, are important risk
factors for the development of acute renal failure (ARF).1 The
prevalence of ARF secondary to sepsis ranges from 9 to 40%,2
with mortality rates as high as 80% as compared to
approximately 45% observed in ARF secondary to other
causes.3,4
A variety of substances are released in the systemic
circulation as a consequence of endotoxemia. Cytokines
increase the synthesis of nitric oxide, leading to marked
reduction in vascular resistance,5 and compensatory re-
sponses to vasodilation involve the elevation of circulating
vasopressor hormones, including angiotensin II (Ang II).6
Despite the predominance of low systemic vascular resis-
tance, regional perfusion imbalances are frequently observed
in sepsis. Increased sympathetic tone and renin–angiotensin
system (RAS) activity induce renal hypoperfusion and
ischemic damage, and certainly contribute to sepsis-related
ARF.7,8 In animal models of sepsis, as well as in human
patients, renal blood flow (RBF) is quite variable.9 Even in
the presence of relatively normal systemic hemodynamics,
most experimental studies show that global RBF declines
after induction of sepsis10 owing to impaired renal auto-
regulation, with subsequent reduction in renal perfusion
pressure and glomerular filtration rate (GFR).11–13 While
severe and prolonged hypoperfusion plays a relevant role in
sepsis-induced renal damage, it is certainly not the only
factor involved. In fact, it has been shown that ARF
secondary to sepsis develops even in the absence of
hemodynamic compromise and it is worth noting that renal
function deterioration has also been described with preserved
RBF.9 A direct renal action of endotoxins has also been
suggested, as resident renal cells may interact with lipo-
polysaccharides (LPS).14–16 Mechanisms involved are com-
plex and depend on bacterial products and host local and
systemic responses. The relative importance of each one of
these players has not been determined owing to strong and
frequent interactions among them.17 Rat kidney perfusion
with polymorphonuclear cells activated by LPS (but not
organ perfusion with LPS alone) significantly reduced the
GFR, implying that LPS does not affect directly the renal
function.18,19 On the other hand, several experimental studies
have demonstrated that endotoxins can activate renal
epithelial, endothelial and mesangial cells (MC) by direct
means.14,15,20,21 Glomerular MC express mCD14, a toll-like
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receptor-associated cell surface protein.22,23 MC toll-like
receptor 4 are stimulated by LPS–LPS binding-protein
complexes and, through the activation of NF-kB pathway,
synthesize a series of inflammatory mediators.17,24 In
addition, MC produce are critically regulated by direct and
indirect action of various vasoactive substances, usually
present in increased levels during sepsis. These substances
modulate glomerular hemodynamics by regulating differen-
tial pressures between afferent and efferent arterioles, and
between the glomerular and tubular regions. At the same
time, they also participate in the control of Kf.
25
In the past years, attention has been directed to a local
renal RAS, regulated independently from the systemic RAS
and presenting autocrine and paracrine effects. In addition to
a prominent role in the regulation of glomerular hemo-
dynamics, local production of Ang II is also related to other
biological processes, such as apoptosis, vascular remodeling,
cell proliferation and extracellular matrix accumulation.26,27
Furthermore, it has been demonstrated that other peptides
from the RAS, namely Ang 1–7, Ang III, and Ang IV, possess
biological activity in renal cells.28,29 In vivo studies previously
performed in our laboratory demonstrated that systemic
administration of the Ang I-converting enzyme (ACE)
inhibitor captopril prevented Escherichia coli LPS-induced
reductions in RBF and GFR, suggesting the participation of
RAS in renal ischemia secondary to endotoxemia.12 However,
little information is available on the activation status and role
of the local renal RAS in the context of sepsis. Direct actions
of LPS on human MC may modulate Ang II production and
participation in sepsis-induced ARF in any of its different
phases (installation, maintenance and/or recovery). Thus, the
present study was conceived to address this point in an
experimental setting unaffected by systemic factors. Here, we
show that LPS significantly reduces the production of Ang II
in human mesangial cells (HMC) in culture. This effect
appears to be related to rapid-onset and long-lasting
inhibition of renin activity.
RESULTS
HMC express main RAS components
We initially confirmed the presence of RAS members in
HMC. Through experiments of quantitative real-time reverse
transcriptase-polymerase chain reaction, constitutive expres-
sion of angiotensinogen, renin, and ACE mRNA was readily
detected in HMC. Levels of expression of the transcripts were
comparable to those observed in human liver, kidney, and
umbilical vein endothelial cells, respectively (Figure 1). In
addition, Ang I and Ang II were also identified under basal
conditions through high-performance liquid chromatogra-
phy (HPLC) and confirmed by mass spectrometry (data not
shown).
LPS reduces Ang II levels in HMC
E. coli LPS administration produced rapid (1 h) time- and
concentration-dependent reductions in HMC Ang II levels
(Figures 2a and c). Maximal inhibitory action was obtained
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Figure 1 | Representative quantitative real-time PCR amplifica-
tion curves. Human MC and positive control cDNAs were amplified
using (a) angiotensinogen, (b) renin and (c) ACE specific primers.
Experiments were repeated at least two times.
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Figure 2 | LPS reduces Ang I and II levels in HMC. (a, b) Time-
dependent effect of LPS (100 mg/ml) on cell lysate and extracellular
concentrations of Ang II and Ang I, respectively. Values are
mean7s.e.m. of seven experiments. *Po0.01; **Po0.001 compared
to controls. (c, d) Concentration-dependent effect of LPS (incubated
for 3 h) on Ang II and Ang I MC concentrations. Values are
mean7s.e.m. of four experiments. *Po0.05; **Po0.01 compared
to controls.
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at 3 h with 100 mg/ml LPS. Endotoxin-induced decrements in
Ang II levels were maintained for up to 72 h (data not
shown). In order to rule out trafficking of Ang II induced by
LPS, we analyzed peptide levels in the cell lysate and in the
extracellular medium. Although different in magnitude, LPS
response profile was essentially the same when both
compartments were evaluated (Figure 2a), suggesting actual
inhibition of the RAS in HMC. In addition, Ang II was not
reduced as a consequence of MC death, as viability was
higher than 95% after 72 h of incubation with 100 mg/ml LPS
(n¼ 4, P¼ 0.54 vs vehicle).
LPS does not induce angiotensin catabolism or ACE inhibition
Considering the magnitude and time course of the events
observed, LPS-triggered Ang II degradation was investigated.
We searched for increments in the concentrations of six
peptides downstream in RAS metabolic pathway (Ang III,
Ang 1–7, Ang 1–6, Ang 1–5, Ang 4–8, and Ang 5–8), and the
exact opposite was found, with significant reduction in levels
of all peptides studied in the cell lysate and/or extracellular
medium (Table 1). As seen for Ang II, diminution was
already observed after 1 h of LPS administration. We also
considered ACE inhibition as a possible cause for decreased
Ang II availability in our system. Surprisingly, analysis of
ACE activity in lysates from HMC treated with LPS for 1 h
showed a small but significant increase in the rate of
conversion of Ang I to Ang II (Figure 3).
Renin (or renin-like) activity is inhibited by LPS
The data from Ang II metabolite and ACE activity analyses
suggested that LPS affects upstream player(s) in the RAS
pathway. The measurement of Ang I concentration corrobo-
rated this hypothesis. Figure 2b shows that Ang I levels are
significantly reduced both in the cell lysate and in the
extracellular medium following 1 h of LPS administration.
Maximal inhibition was observed after 3 h (Figure 2d) and, as
observed for Ang II, this response perdured for at least 48 h
(data not shown).
In an attempt to narrow down the number of possible
targets for LPS, we exposed HMC to 30 mM glucose for 72 h
and the production of Ang II was evaluated in the absence
and in the presence of LPS. As can be seen in Figure 4, LPS
leads to a significant reduction of 75% in Ang II levels in
HMC. On the other hand, glucose produced an increase in
Ang II concentration of 17% (Po0.05). When both forms of
treatment were combined, LPS effect on Ang II levels was
abolished. In addition, mannitol did not affect Ang II
production by HMC, neither in the absence nor in the
presence of LPS (Figure 4), confirming the specificity of the
effect of glucose. Renin and angiotensinogen have been
pointed out as RAS members affected by high glucose
ambient. Thus, we designed experiments to evaluate the
possible inhibitory effect of LPS on renin activity, eliminating
the influence of substrate availability. HMC were incubated
for 1 h with angiotensinogen in excess and LPS was added to
the culture medium for another hour thereafter. Extracellular
medium was collected and Ang I concentration measured.
Figure 5 demonstrated that, as witnessed before, LPS reduced
the levels of Ang I. Also as expected, the increased availability
of the substrate angiotensinogen produced significant incre-
ments of 54% in the concentration of Ang I. On the other
hand, the presence of 1 mM angiotensinogen was not sufficient
to eliminate the inhibitory effect of LPS. Ang I level
increments in the group LPS plus angiotensinogen compared
to LPS alone were smaller in relative and absolute terms in
relation to the elevation observed in the group angiotensino-
gen alone in comparison to basal conditions. We also
evaluated angiotensinogen protein levels and, as depicted in
Figure 6, no significant LPS-induced modification was
detected. Taken together, these data suggest that renin
activity and/or protein expression levels were negatively
affected by LPS. Additional experiments demonstrated that
renin protein levels were unaffected by treatment with
maximal concentrations of LPS (Figure 6).
DISCUSSION
We have demonstrated that in vitro administration of LPS
significantly reduced the levels of Ang II in HMC in a time-
and concentration-dependent manner. Of interest, LPS effect
was detectable as early as 1 h after its addition to culture
medium, and maintained for up to 72 h. The time course of
Table 1 | LPS (100 lg/ml, 1–3 h) reduces Ang I and Ang II
metabolic fragments in cultured HMC
Cell lysate Culture medium
Fragments 1 h 3 h 1 h 3 h
Ang III 3.4* 4.6** 2.0 1.4*
Ang 1–7 2.1* 2.6** 1.4 1.3
Ang 1–6 6.2* 1.9 2.1 2.0*
Ang 1–5 2.6* 2.9** 1.2 1.5*
Ang 4–8 2.3** 1.8* 2.6 +1.2
Ang 5–8 1.9** 1.8** 2.2 1.7*
HMC=human mesangial cell; LPS=lipopolysaccharide.
Values are expressed as LPS/control fold-change.
*Po0.05, **Po0.01 compared to controls. (N=7).
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Figure 3 | Effect of LPS (100 lg/ml, 1 h) on ACE activity in HMC.
Values are mean7s.e.m. of 11 experiments. *Po0.05 compared to
control.
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LPS inhibitory effect on the mesangial RAS makes transcrip-
tional modulation of members of this system less probable.
Another hypothesis would involve LPS-mediated degradation
of Ang II. However, levels of angiotensin metabolites were
found to be reduced both in cell lysates and extracellular
medium at all time points analyzed. Modification of levels or
activation state of ACE also does not explain our findings, as
the enzyme activity was slightly but significantly increased in
comparison to controls. We speculate that regulatory feed-
back mechanisms operate this modification. This finding also
argues against nonspecific protein degradation induced by
LPS. As Ang I levels were also affected by LPS, we targeted
more proximal steps in the Ang II metabolic pathway. High
ambient glucose can stimulate angiotensinogen production,
and renin and cathepsin B activity.30–32 As such, we used this
model as a tool to dissect LPS possible mechanism of action.
LPS-induced reduction of Ang II levels was prevented by
coincubation of HMC with 30 mM glucose and this effect was
not related to the associated hyperosmolar state. These results
associated with the demonstration of lower levels of Ang I
following endotoxin treatment restricted the number of
possible targets for LPS in HMC. It is widely described that
renin activity is a limiting step in the synthesis of Ang II.
Thus, we assessed the enzymatic activity of renin in HMC
while still in culture. In order to remove any interference of
modifications in endogenous levels of angiotensinogen,
human recombinant protein was added in excess to cell
cultures treated with LPS for 1 h and Ang I levels were then
evaluated. While Ang I concentration markedly increased
following angiotensinogen incubation in cells treated with
vehicle, this response was blunted in a significant manner in
cultures exposed to LPS. This finding demonstrates that LPS
affects negatively renin and/or enzymes with renin-like
activity. Western blot analysis indicated that levels of renin
protein were stable after LPS administration, eliminating
degradation and/or decreased synthesis as the motive for
reduced enzymatic activity.
We have not identified the mechanisms by which LPS
inhibits renin or renin-like activity. All components needed
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Figure 4 | High ambient glucose prevents LPS-induced Ang II
reduction in HMC. Cells were incubated with 5 mM glucose (C),
30 mM glucose (HG), 5 mM glucoseþ 25 mM mannitol (M), 5 mM
glucoseþ 100mg/ml LPS (LPS), 5 mM glucoseþ 25 mM manni-
tolþ 100 mg/ml LPS (Mþ LPS), or 30 mM glucoseþ 100 mg/ml LPS
(HGþ LPS) for 72 h. Values are mean7s.e.m. of five to seven
experiments. *Po0.005 compared to C; #Po0.005 compared to LPS.
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Figure 5 | Angiotensinogen (AGT) in excess failed to prevent LPS-
induced Ang I reduction in HMC. Cells were incubated with vehicle
(control) or LPS (100 mg/ml) for 1 h and subsequently with vehicle or
AGT (1 mM) for another hour. Values for Ang I concentration are
means7s.e.m. of six experiments. *Po0.001 compared to AGT.
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Figure 6 | (a) Western blot analysis showing angiotensinogen
(AGT), renin, and a-actin protein expression levels in HMC
treated with vehicle or LPS (100 lg/ml) for 1 h. Results are
representative of at least two separate experiments. (b) Relative AGT
and renin protein expression of LPS treatment compared to control.
Results were normalized by a-actin protein expression. Values are
mean7s.e.m. of three experiments.
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for LPS receptor-mediated actions in HMC were in place in
our model. It has been reported that mCD14 and toll-like
receptor 4 are constitutively expressed in MCs.22,23,33 In
addition, our experiments were performed in the presence of
serum, in order to guarantee minimal necessary concentra-
tions of LPS-binding protein in our system. In accordance
with this hypothesis, concentration–response effects were
observed. As Ang II levels were significantly reduced in early
time points, rapid-onset cellular changes would have to take
place following LPS receptor activation. It has been described
that LPS activates different biochemical pathways in various
biological systems in a time course compatible with our
results. Mitogen-activated protein kinase phosphorylation,
calcium mobilization, nitric oxide release and/or transcrip-
tion factor nuclear translocation within minutes after LPS
administration have been reported.34–36 So far, our attempts
to identify modifications in intracellular calcium concentra-
tions, nitric oxide levels, and nuclear translocation of NF-kB
have been unsuccessful (data not shown). Direct effects of
LPS on renin protein and/or cofactors are also a possibility.
To the best of our knowledge, no molecular interaction
between LPS and renin has been published. Nevertheless, we
believe that this phenomenon deserves further analysis. We
are currently devising methods to investigate potential physi-
cal interactions between LPS and renin or renin-associated
proteins.
It is interesting to consider the repercussion of our
findings on renal hemodynamics should they be reproducible
in vivo. As far as we know, there is no conclusive data in the
literature that MCs are directly affected by Gram-negative
endotoxins in vivo. However, indirect evidence strongly
suggests this possibility. We and others have demonstrated
that these cells respond to LPS in vitro in different
ways.14,15,37 As already mentioned, all the necessary elements
for LPS signal transduction are present in MC. Moreover,
LPS systemic injection produces acute glomerular injury in
mice, but there is no indication that LPS trespasses the
endothelial layer or whether these effects are secondarily
mediated by released cytokines.38 Inflammatory changes in
glomerular microvasculature may facilitate the access of LPS
to MC. Glomerular endothelial apoptosis following LPS
administration has been demonstrated in vitro and in
vivo.16,39 Thus, it is reasonable to infer that increased
capillary permeability would expose MC to amphiphilic,
relatively small-sized (B10 kDa), LPS molecules.40 Endotox-
in effects on systemic RAS are well characterized. Plasma
renin activity and Ang II concentrations are markedly
increased mostly as a secondary effect of hemodynamic
compromise of sepsis.7,8 Whereas still object of some debate,
it appears that efferent arteriolar tone is more sensitive to
Ang II than its afferent counterpart. Although we have not
addressed this question, we speculate that reduced intraglo-
merular renin activity and production of Ang II would reflect
on efferent arteriolar tone, participating in the blunted
response of this vascular territory to systemically released
vasoconstricting mediators. In this case, the direct effects of
LPS on MC would contribute to reducing PGC and
consequently single nephron GFR. One should also analyze
the possible effects of LPS on Kf, as MC contractile status
would be affected by decreased levels of Ang II. Diminished
MC tone would produce relative increments in glomerular
filtration surface and Kf. However, this effect might not be
sufficient to attenuate the decrease in single nephron GFR,
particularly in conditions of reduced RBF, commonly
observed in septic states. In addition, different papers report
a reduced Kf during sepsis.
41,42 Thus, if filtration surface is
indeed increased owing to MC reduced contractility, k should
also be markedly diminished in order to produce net
decrements in Kf. Inhibition of the local RAS could also
impact other cell types including glomerular endothelial cells,
podocytes, and vascular smooth muscle cells, directly or
indirectly responsible for the modulation of Kf and PGC. The
pathophysiology of septic ARF is poorly understood.1 Even in
the presence of changes in renal hemodynamics and
significant tubular damage, structural alterations of the
glomerulus are rarely seen in microscopic analysis of kidney
fragments obtained from patients with sepsis-related
ARF.43,44 Similar results are found in experimental studies.45
Nonetheless, glomerular modifications secondary to the
inflammatory response generated by sepsis have been
described. As an example, TNF-a released from MC may
lead to leukocyte accumulation in the glomerulus, as well as
apoptotic death of glomerular endothelial cells.16 Ang II is
known as a proliferative and antiapoptotic agent for
mesangial and microvascular endothelial cells.46,47 We have
demonstrated that the negative effect of LPS on Ang II
production by MC lasts as long as 72 h. Therefore, it is
conceivable that recovery from ARF could also be affected if
persistent intraglomerular RAS inhibition is observed in vivo
following resolution of the acute phase of sepsis.
In conclusion, our results demonstrate that direct
administration of E. coli LPS reduces the production of
Ang II by HMC in culture. This early-onset, long-lasting
effect appears to be mediated by inhibition of renin or renin-
like activity. Diminished intraglomerular availability of Ang
II might influence glomerular hemodynamics and/or renal
regeneration in sepsis-related renal dysfunction, and addi-
tional studies are underway to test this hypothesis. We
anticipate that our findings may help to better understand
the mechanisms involved in the genesis, maintenance and/or
recovery from ARF secondary to septic states.
MATERIALS AND METHODS
HMC culture and experimental conditions
All experiments were performed with immortalized HMC, kindly
donated by Dr Bernhard Banas (Munich, Germany). Cells between
passages 54 and 58 were cultured in Dulbecco’s modified Eagle’s
medium (Invitrogen, Carlsbad, CA, USA) containing 5 mM glucose
and supplemented with 10% fetal bovine serum. Cells were
maintained in a humidified incubator at 371C and 5% CO2. After
reaching confluence, cells were washed with phosphate-buffered
saline and kept for 24 h in Dulbecco’s modified Eagle’s medium
supplemented with 0.5% fetal bovine serum. E. coli LPS (serotype
978 Kidney International (2006) 69, 974–980
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0111-B4; Sigma Co., St Louis, MO, USA) or its vehicle were added at
variable concentrations and maintained in contact with cell cultures
for up to 72 h. At different time points, extracellular medium was
removed and cells were washed twice in cold phosphate-buffered
saline. Cell cultures were scraped in ice-cold 1 mM Tris-HCl buffer,
and cell lysates and media were stored at 701C for subsequent
analysis of concentration and/or activity of different components of
the RAS. In a separate series of experiments, confluent HMC were
incubated in 30 mM glucose or mannitol for 72 h, and LPS (100 mg/
ml) or vehicle were added. In addition, experiments were designed
to evaluate renin activity while cells were still in culture. Briefly,
quiescent cells kept in serum-free medium for 24 h were incubated
with LPS (100 mg/ml) or vehicle (in the presence of 0.5% fetal
bovine serum) for 1 h. Human recombinant angiotensinogen (1 mM,
a kind gift from Dr Pierre Corvol, Paris, France48) was then added
for 1 h and extracellular medium was saved for Ang I concentration
determination as an indirect measure of renin activity.
Cell viability
Cell necrosis was evaluated by a fluorescent dye exclusion method
employing an acridine orange (3 mg/ml)þ ethidium bromide (3mg/
ml) mixture, as described elsewhere.49 Cell apoptosis was analyzed
according to chromatin morphology after staining with the
fluorescent dye Hoechst 33342 (5mg/ml). Cells with intact plasma
membrane and no evidence of apoptosis were considered viable.
Quantitative real-time reverse transcriptase-polymerase
chain reaction
Total RNA was extracted from cell pellets (Rneasy kit, Qiagen Inc.,
Hilden, Germany), and reverse transcriptase reaction (T-Primed
Ready-to-Go kit, Amersham Biosciences, Upsala, Sweden) was
performed with 1 mg of DNAse I-treated RNA. Quantitative real-
time reverse transcriptase-polymerase chain reaction was carried out
using ABI Prism 7700 sequence detector (Applied Biosystems, Foster
City, CA, USA) and the Quantitect SYBR Green I kit (Qiagen Inc.,
Germany).
Determination of angiotensin concentration
Intra- and extracellular levels of Ang I, Ang II, and their metabolites
(Ang III, Ang 1–7, Ang 1–5, Ang 4–8, Ang 5–8, Ang 1–6) were
analyzed by HPLC. Briefly, peptides of interest from cell lysate or
medium were extracted and purified in Sep-Pak-C18 columns
(Waters Corporation, Milford, MA, USA) according to method
already established in our laboratory.50 One hundred microliters of
each sample were filtered and injected into the HPLC system.
Angiotensin peptides were analyzed by reverse-phase HPLC using an
aquapore ODS 300 column (7mm, 4.6 250 mm; Applied Biosys-
tems) equilibrated with 0.1% phosphoric acid containing 5% (vol/
vol) acetonitrile. Angiotensin peptides were separated by isocratic
elution for 5 min, followed by a 20 min 5–35% acetonitrile linear
gradient in 0.1% (vol/vol) phosphoric acid under a flow rate of
1.5 ml/min. The chromatographic profile of each sample was
compared with that obtained for standard intact and fragmented
peptides (Sigma Co.) of the RAS at 214 nm absorbance. Peptides
were identified according to retention time and quantified by area
integration using repeated injections of standard peptide solution to
correct for small differences in retention time (o6%) and peak
height (o5%). The identity of eluted peptides separated by HPLC
(Ang I and Ang II, and metabolites) was confirmed by direct
sequencing (protein sequencer PPSQ-23; Shimadzu Corp., Tokyo,
Japan). For concentration determination, commercially available
peptides were employed to develop standard curves. Only curves
with a correlation coefficient higher than 0.98 were accepted. A
linear relationship between peak area and mass was obtained for all
peptides studied. The lower limit of quantification determined was
approximately 100 pg. Peptide levels were normalized according to
total protein concentration determined in cell lysates by Bradford
technique, and the results were expressed as ng/mg of cell protein.
ACE activity
HMC were treated with LPS (100 mg/ml) or vehicle for 1 h. Cells
were washed twice with ice-cold phosphate-buffered saline, scraped
in 2 ml of phosphate-buffered saline and centrifuged at 3000 r.p.m.
for 10 min. The supernatant was discarded and the cell pellet stored
at 801C. The pellet was resuspended in 100 mM Tris-HCl buffer
containing 50 mM NaCl and 10 mM ZnCl2, pH 7.0, sonicated, and
centrifuged (3000 r.p.m.) for 10 min at 41C. Hydrolysis rate of the
intramoleculary quenched fluorogenic substrate Abz-YRK-(Dnp)p
(10mM) incubated with aliquots of cell lysate for 30 min at 371C was
assessed to obtain ACE enzymatic activity. Fluorescence increments
along the time were read at 420 nm (excitation: 320 nm). ACE
activity was expressed as mmol/min/mg of protein.
Western blot
Protein samples were separated by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis and transferred to nitrocellulose
membranes. Nonspecific binding sites were blocked for 1 h with 5%
skim milk. Membranes were washed with TBS-T buffer (0.05%
Tween-20, 20 mM Tris, 150 mM NaCl, pH 7.5) and incubated
overnight with rabbit anti-human renin polyclonal antibody
(1:100; Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) or
sheep anti-human angiotensinogen antibody (1:200; a kind gift from
Dr S Kumar, Birmingham, UK) at room temperature. Membranes
were washed three times with TBS-T buffer and incubated
for 1 h with secondary biotin-conjugated antibodies (1:2000; Santa
Cruz Biotechnology). Membranes were washed again and incubated
with streptavidin–alkaline phosphatase for 30 min. Signals were
detected by BCIP/NBT (Bio-Rad, Hercules, CA, USA). Densitome-
try was performed and image was acquired and analyzed with the
software Quantity One (Bio-Rad). Data were expressed as
relative units and a-actin expression levels were used to normalize
the results.
Statistical analysis
Results were expressed as means7s.e.m. Different groups were
compared by unpaired Student’s t-test. Relative values of angio-
tensin concentration (LPS/control) were log2-transformed before
analysis. Po0.05 was considered significant.
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